‘I’m Still Here’: Janet Woodcock’s Swan Song At US FDA Looking Like A Longer-Term Job
Janet Woodcock’s imminent departure from the agency has been predicted often during her tenure. Her latest project may keep her there longer than even she thought possible.
You may also be interested in...
Some US FDA Decisions May Have Been Different If Technology Had Been Upgraded, Woodcock Says
Principal Deputy Commissioner Woodcock is overseeing an enterprise-wide technology campaign intended to improve access to agency information and data.
Woodcock Focusing On Food Issues, Rather Than Drugs, As US FDA’s Principal Deputy Commissioner
Commissioner Robert Califf wants Woodcock to improve food operations and processes, but lawmakers question whether she is the best overseer for the area.
Office Of New Drugs Reorg Is Bigger Than Expected: US FDA Adds 11 Review Divisions
Long-planned OND 'modernization' to better match workflow, allow more time with stakeholders includes proposed restructuring that would boost number of offices overseeing review operations (adding four for a total of nine) and drug review divisions (adding 11 for a total of 30).